NCT07180264Recruiting
Trastuzumab Deruxtecan in Advanced Breast Cancer
Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 118 (estimated)
- First submitted
- 11 Sept 2025
- Start date
- 28 Aug 2025
- Primary completion date
- Feb 2027
- Lead sponsor
- Wenjin Yin
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07180264
What you commit to
- Study type: Observational
- Planned participants: 118
- From 28 Aug 2025 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- During pregnancy and lactation
Who the study is looking for
- Aged ≥18 and older
- Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
- ECOG 0-1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.